Patents
Sitemap › C07 - Organic chemistry › C07D - Heterocyclic compounds
More topics under "C07D - Heterocyclic compounds" (1,537,440)
C07D 201 - Preparation, separation, purification, or stabilisation of unsubstituted lactams (2,192)
C07D 203 - Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom (1,097)
C07D 205 - Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom (6,868)
C07D 207 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom (40,304)
C07D 209 - Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom (45,780)
C07D 211 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings (37,939)
C07D 213 - Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members (63,273)
C07D 215 - Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems (27,676)
C07D 217 - Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems (11,865)
C07D 219 - Heterocyclic compounds containing acridine or hydrogenated acridine ring systems (2,120)
C07D 221 - Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups (10,931)
C07D 223 - Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom (8,732)
C07D 225 - Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom (1,649)
C07D 227 - Heterocyclic compounds containing rings having one nitrogen atom as the only ring hetero atom, according to more than one of groups (473)
C07D 229 - Heterocyclic compounds containing rings of less than five members having two nitrogen atoms as the only ring hetero atoms (515)
C07D 231 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings (25,550)
C07D 233 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings (34,408)
C07D 235 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings (15,325)
C07D 237 - Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings (8,468)
C07D 239 - Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings (42,619)
C07D 241 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings (18,673)
C07D 243 - Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms (5,961)
C07D 245 - Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms (898)
C07D 247 - Heterocyclic compounds containing rings having two nitrogen atoms as the only ring hetero atoms, according to more than one of groups (239)
C07D 249 - Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms (17,749)
C07D 251 - Heterocyclic compounds containing 1,3,5-triazine rings (10,913)
C07D 253 - Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group (2,967)
C07D 255 - Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups (739)
C07D 257 - Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms (9,612)
C07D 259 - Heterocyclic compounds containing rings having more than four nitrogen atoms as the only ring hetero atoms (488)
C07D 261 - Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings (11,459)
C07D 263 - Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings (20,978)
C07D 265 - Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms (11,132)
C07D 267 - Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms (2,022)
C07D 269 - Heterocyclic compounds containing rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms according to more than one of groups (111)
C07D 271 - Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms (7,144)
C07D 273 - Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups (2,368)
C07D 275 - Heterocyclic compounds containing 1, 2-thiazole or hydrogenated 1,2-thiazole rings (4,972)
C07D 277 - Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings (33,621)
C07D 279 - Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms (5,149)
C07D 281 - Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms (1,924)
C07D 283 - Heterocyclic compounds containing rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms, according to more than one of groups (102)
C07D 285 - Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups (9,964)
C07D 291 - Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms (1,087)
C07D 293 - Heterocyclic compounds containing rings having nitrogen and selenium or nitrogen and tellurium, with or without oxygen or sulfur atoms, as the ring hetero atoms (553)
C07D 295 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms (34,005)
C07D 301 - Preparation of oxiranes (10,136)
C07D 303 - Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom (12,512)
C07D 305 - Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms (5,442)
C07D 307 - Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom (47,108)
C07D 309 - Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings (12,815)
C07D 311 - Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings (24,127)
C07D 313 - Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom (3,580)
C07D 315 - Heterocyclic compounds containing rings having one oxygen atom as the only ring hetero atom according to more than one of groups (1,360)
C07D 317 - Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms (18,224)
C07D 319 - Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms (10,283)
C07D 321 - Heterocyclic compounds containing rings having two oxygen atoms as the only ring hetero atoms, not provided for by groups (2,079)
C07D 323 - Heterocyclic compounds containing more than two oxygen atoms as the only ring hetero atoms (1,581)
C07D 325 - Heterocyclic compounds containing rings having oxygen as the only ring hetero atom according to more than one of groups (168)
C07D 327 - Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms (2,428)
C07D 329 - Heterocyclic compounds containing rings having oxygen and selenium or oxygen and tellurium atoms as the only ring hetero atoms (47)
C07D 331 - Heterocyclic compounds containing rings of less than five members, having one sulfur atom as the only ring hetero atom (456)
C07D 333 - Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom (32,883)
C07D 335 - Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom (4,725)
C07D 337 - Heterocyclic compounds containing rings of more than six members having one sulfur atom as the only ring hetero atom (875)
C07D 339 - Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms (3,352)
C07D 341 - Heterocyclic compounds containing rings having three or more sulfur atoms as the only ring hetero atoms (281)
C07D 343 - Heterocyclic compounds containing rings having sulfur and selenium or sulfur and tellurium atoms as the only ring hetero atoms (52)
C07D 345 - Heterocyclic compounds containing rings having selenium or tellurium atoms as the only ring hetero atoms (419)
C07D 347 - Heterocyclic compounds containing rings having halogen atoms as ring hetero atoms (38)
C07D 401 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom (107,979)
C07D 403 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group (62,587)
C07D 405 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom (69,397)
C07D 407 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group (11,963)
C07D 409 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms (52,226)
C07D 411 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms (2,465)
C07D 413 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms (64,687)
C07D 415 - Heterocyclic compounds containing the thiamine skeleton (90)
C07D 417 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group (62,773)
C07D 419 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms (1,431)
C07D 421 - Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms (480)
C07D 451 - Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.02,4] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof (5,273)
C07D 453 - Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids (5,704)
C07D 455 - Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine (2,122)
C07D 457 - Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula: , e.g. lysergic acid (836)
C07D 459 - Heterocyclic compounds containing benz [g] indolo [2, 3-a] quinolizine ring systems, e.g. yohimbine; 16, 18-lactones thereof, e.g. reserpic acid lactone (97)
C07D 461 - Heterocyclic compounds containing indolo [3, 2, 1-d, e] pyrido [3, 2, 1-i, j] [1, 5]-naphthyridine ring systems, e.g. vincamine (286)
C07D 463 - Heterocyclic compounds containing 1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula: , e.g. carbacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring (613)
C07D 471 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups (64,559)
C07D 473 - Heterocyclic compounds containing purine ring systems (11,932)
C07D 475 - Heterocyclic compounds containing pteridine ring systems (2,718)
C07D 477 - Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula: , e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring (2,484)
C07D 487 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups (57,272)
C07D 489 - Heterocyclic compounds containing 4ah-8, 9 c- iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: (2,334)
C07D 491 - Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups , , or (29,726)
C07D 493 - Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system (17,376)
C07D 495 - Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms (21,336)
C07D 497 - Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms (1,069)
C07D 498 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms (21,960)
C07D 499 - Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula: , e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring (3,448)
C07D 501 - Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula: , e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring (7,574)
C07D 503 - Heterocyclic compounds containing 4-oxa-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula: , e.g. oxapenicillins, clavulanic acid derivatives; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring (648)
C07D 505 - Heterocyclic compounds containing 5-oxa-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula: , e.g. oxacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring (556)
C07D 507 - Heterocyclic compounds containing a condensed beta-lactam ring system, not provided for by groups , or; Such ring systems being further condensed (161)
C07D 513 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups , or (15,120)
C07D 515 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups , or (877)
C07D 517 - Heterocyclic compounds containing in the condensed system at least one hetero ring having selenium, tellurium, or halogen atoms as ring hetero atoms (452)
C07D 519 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or (11,041)
C07D 521 - Heterocyclic compounds containing unspecified hetero rings (16,203)
Patents for C07D - Heterocyclic compounds (10,420)
08/2002
08/07/2002CN1362959A C10 carbamoyloxy substituted taxanes as antitumor agents
08/07/2002CN1362958A C7 carbonate substituted taxanes as antitumor agents
08/07/2002CN1362957A C17 heterosubustituted acetate taxanes as antitumor agents
08/07/2002CN1362956A C7 carbamoyloxy substituted taxanes as antitumor agents
08/07/2002CN1362954A Sulfamato hydroxamic acid metalloprotease inhibitor
08/06/2002US6429210 Orthorombic polymorph of clopidogrel hydrogen sulfate with improved stability and lower solubility; antithrombotic agent; specific crystal structure and thermodynamic properties
08/01/2002WO2002059127A2 Pyrazinoquinoxaline derivatives as serotonin agonists and antagonists
08/01/2002WO2002059124A2 Substituted pyrroloquinolines and pyridoquinolines as serotonin agonists and antagonists
08/01/2002WO2002059112A2 Pyrazole compounds useful as protein kinase inhibitors
08/01/2002WO2002059111A2 Pyrazole compounds useful as protein kinase inhibitors
08/01/2002WO2002059110A1 Pyrimidineamines as angiogenesis modulators
08/01/2002WO2002059083A2 Novel compounds
08/01/2002WO2002058734A2 Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions
08/01/2002WO2002058732A2 Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
08/01/2002US20020103209 Serotonergic modulators; for treatment of disorders of the central nervous system including psychotic disorders, hypertension and vascular disorders, migraine
08/01/2002US20020103204 Piperazinyl)-3-(2-(3-(4-morpholinylmethyl)phenoxy)ethoxy) pyrazine derivatives; for prophylaxis or treatment of serotonin-related diseases
08/01/2002CA2563051A1 Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
08/01/2002CA2434504A1 Combinations of sterol absorption inhibitor(s) with blood modifiers for treating vascular conditions
08/01/2002CA2431970A1 Substituted pyrazinoquinoxaline derivatives as serotonin receptor agonists and antagonists
07/2002
07/31/2002EP1227095A2 A process for the purification of (S)-4-((3-(dimethylamino)ethyl)-1H-indol-5yl)-methyl)-2-oxazolidinone
07/31/2002EP1227092A2 Isonitrile intermediates for the preparation of tri-substituted imidazole compounds with multiple therapeutic properties
07/31/2002EP1227091A2 Formamide intermediates for the preparation of tri-substituted imidazole compounds with multiple therapeutic properties
07/31/2002EP1227088A1 Crystalline base of citalopram and hydrochoride or hydrobromide salt thereof
07/31/2002EP1226137A1 Phenyl- and pyridyl-tetrahydro-pyridines having tnf inhibiting activity
07/31/2002EP0854867B1 Tetrahydroquinolines as nmda antagonists
07/31/2002EP0527801B1 Thiophene sulfonamides useful as carbonic anhydrase inhibitors
07/31/2002CN1361765A Inhibitors of aspartyl protease
07/31/2002CN1360890A Use of active retiene derivative with negative hormone and/or antagonist
07/30/2002US6426337 Antiinflammatory agents
07/25/2002WO2002057267A1 Compounds specific to adenosine a1, a2a, and a3 receptor and uses thereof
07/25/2002WO2002057259A2 Pyrazole compounds useful as protein kinase inhibitors
07/25/2002WO2002042268A3 Ep4 receptor selective agonists in the treatment of osteoporosis
07/25/2002WO2002032901A3 Bridged piperazine derivatives
07/25/2002US20020099217 Process for preparing azacycloalkanoylaminothiazoles
07/25/2002US20020099212 Sulfonamide compounds and pharmaceutical use thereof
07/25/2002US20020099068 I kappa B kinase inhibitors for treating various disorders including arthritis
07/25/2002CA2430577A1 Compounds specific to adenosine a1, a2a, and a3 receptor and uses thereof
07/24/2002EP1224179A2 Sodium-hydrogen exchanger type 1 inhibitor crystals
07/24/2002EP1224172A1 Drugs for the treatment of malignant tumours
07/24/2002EP0741716B1 Delta 12,13 -iso-taxol analogs, antineoplastic use and pharmaceutical compositions containing them
07/24/2002CN1360588A Hemisynthetic method and intermediate thereof
07/23/2002US6423842 Act preferentially on m4 receptors; side effect reduction; used to treat nervous system disorders, psychological disorders and as an analgesic; alzheimer's disease; cognition activators.
07/23/2002US6423722 Antiinflammatory agents
07/23/2002CA2041594C Pyrido[2,3-f][1,4]thiazepines and pyrido[3,2-b][1,5]benzothiazepines
07/18/2002US20020094999 Highly selective butyrylcholinesterase inhibitors for the treatment and diagnosis of Alzheimer's disease and dementias
07/17/2002EP1222927A2 Pharmaceutical compositions having appetite suppressant activity
07/17/2002EP1222195A1 Novel thiazolo(4,5-d)pyrimidine compounds
07/17/2002EP1222190A1 5-(2-substituted-5-heterocyclylsulphonylpyrid-3-yl)-dihydropyrazolo[4,3-d]pyrimidin-7-ones as phosphodiesterase inhibitors
07/17/2002EP1222173A1 Process for preparing 4-trifluoromethylsulphinylpyrazole derivative
07/17/2002EP0888340B1 4-(benzo-1,3-dioxolyl)-pyrrolidine-3-carboxylic acid derivatives as endothelin antagonists
07/17/2002EP0766668B1 Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudormophs thereof
07/16/2002US6420359 5,11-Dihydro-11-ethyl-5-methyl-8-(2-((1-oxido-4-quinolinyl)oxy)ethyl)-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one for example; antiviral agents for HIV infection
07/11/2002WO2002053558A1 Quinazolone derivatives as alpha 1a/b adrenergic receptor antagonists
07/11/2002WO2002053542A1 Process for making amlodipine maleate
07/11/2002WO2002053134A1 Pharmaceutical compositions comprising amlodipine maleate
07/11/2002US20020091265 4-phenyl-pyridine derivatives
07/11/2002US20020091262 Armoatic or heteroarmoatic compound containing substituted amides or thioamides
07/11/2002US20020091119 Aralkyl and aralkylidene heterocyclic lactams and imides
07/11/2002US20020091118 Psychotherapeutic agents.
07/11/2002US20020091117 Psychotherapeutic agents.
07/10/2002EP1221314A1 New crystalline form of omeprazole
07/10/2002EP1220856A2 Pyrazolo[4,3-d]pyrimidine derivatives
07/10/2002EP1220842A1 Cyclic amine compounds as ccr5 antagonists
07/10/2002CN1087288C Crystalline [R-(R+,R+)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(5-methylethyl)-3-phenyl-4-(phenylamino) carbonyl]-1H-pyrole-1-heptanoic acid hemi-calcium salt (atorvastatin)
07/09/2002CA2041224C Azatetracycle compounds
07/04/2002US20020086888 Substantially free from amlodipine aspartate side products, by reacting amlodipine or an acid addition salt thereof with excess maleic acid under acidic environment
07/04/2002US20020086874 Substituted indoline derivative compounds which are antagonists of the progesterone receptor; contraceptives; antineoplastic agents
07/04/2002US20020086850 Antiinflammatory agents
07/03/2002EP1218354A1 Quinazoline derivatives and their use as pharmaceuticals
07/03/2002EP1218347A1 Pyrazoloanthrone and derivatives thereof as jnk inhibitors and their compositions
07/03/2002EP0563345B1 Novel 4-arylpiperazines and 4-arylpiperidines
07/03/2002CN1356991A Quinoline and quinoxaline compounds as PDGF-R and/or LCD tyrosine kinase inhibitors
07/03/2002CN1356323A Benzothiazolone derivative
07/02/2002US6414156 Efficent, notoxic process of making new key intermediate quaternary ammonium salts and 2-oxazolylalkyl sulfide derivatives and avoids the reaction of a-haloketones with an azide followed by reducing the resulting a-aminoketone
07/02/2002US6414009 Cardiovascular disorders; anticoagulants
07/02/2002US6413985 Selective antagonists for the strychnine insensitive glycine binding site associated with the nmda receptor complex.
07/02/2002US6413980 Nitrogen containing heterobicycles as factor Xa inhibitors
06/2002
06/27/2002WO2002050066A2 Pyrazole compounds useful as protein kinase inhibitors
06/27/2002WO2002050065A2 Pyrazole compounds useful as protein kinase inhibitors
06/27/2002WO2001051051A3 Agents, such as nicotinamide or cadpr for the treatment of skin disorders
06/26/2002CN1355799A 1-trifluoromethyl-4-hydroxy-7-piperidinyl-aminomethylchroman derivatives
06/26/2002CN1086700C Benzothiophene compounds, intermediates, composition, and methods
06/26/2002CN1086569C Dehydration plant
06/25/2002US6410747 Highly selective butyrylcholinesterase inhibitors for the treatment and diagnosis of alzheimer's disease and dementias
06/25/2002US6410740 Heterocyclylmethyl-substituted pyrazol derivatives
06/25/2002US6410480 Plant safening agents and growth regulators for controlling weeds and grasses; post/preemergence herbicides
06/20/2002US20020077482 Novel intermediates useful for the preparation of antihistaminic piperidine derivatives
06/20/2002US20020077341 C10 carbamoyloxy substituted taxanes
06/19/2002EP1214310A1 Novel photochromic naphthopyrans
06/19/2002EP0980354B1 Vitamin d3 analogs with bis c-20 side chains
06/18/2002US6407237 Crystal forms of 9-substituted hypoxanthine derivatives
06/18/2002US6407104 Pyrrolo[1,2-a]pyrazine spla2 inhibitor
06/13/2002US20020072616 3-azabicyclo[3.1.0]hexane derivatives useful in therapy
06/13/2002US20020072519 Useful as psychotherapeutic agents
06/13/2002DE10041671C1 Verfahren zur Herstellung von Imidazo[1,2-c][2,3]benzodiazepinen sowie Phenylessigsäureester und Oxazol-Derivate als Zwischenprodukte bei deren Herstellung Benzodiazepines process for the preparation of imidazo [1,2-c] [2,3] oxazole and phenylacetic acid esters and derivatives, as intermediates in the preparation thereof
06/12/2002EP1213291A1 Spiro [1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine for use in the treatment of psychotic and intellectual impairment disorders
06/12/2002EP1213020A2 Pharmaceutical compositions having appetite suppressant activity
06/12/2002EP1212320A2 Phenylpiperazines as serotonin reuptake inhibitors
06/12/2002EP1032571B1 Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance p antagonists
06/12/2002EP0885221B1 Azabicyclic esters of carbamic acids useful in therapy
1 ... 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 ... 105